Orgenesis buys cell therapy CMO to cut manufacturing costs and diversify revenue stream
Orgenesis has bought Masthercell SA to take control of production of its Type 1 diabetes cell therapy candidate ahead of clinical trials.
Archives for March 11, 2015
Biobetters may fare better than biosimilars in some therapeutic areas, says analyst
Biobetters stand a better chance of winning market share than lower cost biosimilars in some indications according to new analysis.